MX2017011423A - Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer. - Google Patents
Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer.Info
- Publication number
- MX2017011423A MX2017011423A MX2017011423A MX2017011423A MX2017011423A MX 2017011423 A MX2017011423 A MX 2017011423A MX 2017011423 A MX2017011423 A MX 2017011423A MX 2017011423 A MX2017011423 A MX 2017011423A MX 2017011423 A MX2017011423 A MX 2017011423A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- inflammatory diseases
- immune
- morpholin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 208000026278 immune system disease Diseases 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- -1 dioxothiomorpholino moiety Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL411864A PL236355B1 (pl) | 2015-04-02 | 2015-04-02 | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 |
| PCT/IB2016/051792 WO2016157091A1 (en) | 2015-04-02 | 2016-03-30 | 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011423A true MX2017011423A (es) | 2018-05-17 |
Family
ID=55650626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011423A MX2017011423A (es) | 2015-04-02 | 2016-03-30 | Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10138247B2 (https=) |
| EP (1) | EP3277687B1 (https=) |
| JP (1) | JP6665201B2 (https=) |
| KR (1) | KR102559190B1 (https=) |
| CN (1) | CN107743489B (https=) |
| AU (1) | AU2016241568B2 (https=) |
| BR (1) | BR112017020131B1 (https=) |
| CA (1) | CA2978828A1 (https=) |
| DK (1) | DK3277687T3 (https=) |
| EA (1) | EA032826B1 (https=) |
| ES (1) | ES2765642T3 (https=) |
| HR (1) | HRP20192195T1 (https=) |
| HU (1) | HUE047822T2 (https=) |
| MX (1) | MX2017011423A (https=) |
| PL (2) | PL236355B1 (https=) |
| PT (1) | PT3277687T (https=) |
| SI (1) | SI3277687T1 (https=) |
| WO (1) | WO2016157091A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI885039B (zh) | 2020-01-13 | 2025-06-01 | 美商邊際分析公司 | 經取代吡唑并嘧啶及其用途 |
| WO2022064459A1 (en) * | 2020-09-28 | 2022-03-31 | 1ST Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |
| US20240018151A1 (en) * | 2020-10-19 | 2024-01-18 | Tme Therapeutics Llc | Novel inhibitors of pikfyve and methods using same |
| CN114957261B (zh) * | 2022-05-17 | 2023-06-23 | 重庆文理学院 | 一种具有抗头颈癌作用的化合物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU713673B2 (en) * | 1996-02-07 | 1999-12-09 | Neurocrine Biosciences Inc. | Pyrazolopyrimidines as crf receptor antagonists |
| CN1918172B (zh) | 2003-12-23 | 2011-09-14 | 活跃生物工艺学公司 | 利福霉素类似物及其用途 |
| BRPI0607927A2 (pt) * | 2005-02-11 | 2009-10-20 | Hoffmann La Roche | derivados de pirazol-pirimidina |
| HRP20100516T1 (hr) * | 2006-09-20 | 2010-10-31 | Eli Lilly And Company | Tiazolpirazolopirimidini kao antagonisti receptora crf1 |
| US20110230464A1 (en) | 2007-10-26 | 2011-09-22 | Paul Goldsmith | Purine derivatives useful as p13 kinase inhibitors |
| MX2010009416A (es) | 2008-02-26 | 2010-09-24 | Novartis Ag | Compuestos heterociclicos como inhibidores de cxcr2. |
| CA2721851A1 (en) * | 2008-05-30 | 2009-12-03 | Genentech, Inc. | Purine pi3k inhibitor compounds and methods of use |
| WO2010037765A2 (en) * | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines |
| JP5578490B2 (ja) * | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| BRPI1014572B8 (pt) * | 2009-04-16 | 2022-07-19 | Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii | Imidazopirazinas para uso como inibidores de cinase |
| BRPI1009022A2 (pt) | 2009-05-27 | 2016-03-08 | Hoffmann La Roche | "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit" |
| US8158625B2 (en) * | 2009-05-27 | 2012-04-17 | Genentech, Inc. | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
| GB0912745D0 (en) | 2009-07-22 | 2009-08-26 | Wolfson Microelectronics Plc | Improvements relating to DC-DC converters |
| EP2539337A1 (en) | 2010-02-22 | 2013-01-02 | F. Hoffmann-La Roche AG | Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use |
| US8969364B2 (en) | 2010-03-04 | 2015-03-03 | Merck Sharp & Dohme Corp. | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
| WO2013028263A1 (en) * | 2011-08-24 | 2013-02-28 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as pi3 kinase inhibitors |
-
2015
- 2015-04-02 PL PL411864A patent/PL236355B1/pl unknown
-
2016
- 2016-03-30 JP JP2017551627A patent/JP6665201B2/ja not_active Expired - Fee Related
- 2016-03-30 CN CN201680017259.4A patent/CN107743489B/zh not_active Expired - Fee Related
- 2016-03-30 CA CA2978828A patent/CA2978828A1/en active Pending
- 2016-03-30 HU HUE16714019A patent/HUE047822T2/hu unknown
- 2016-03-30 AU AU2016241568A patent/AU2016241568B2/en not_active Ceased
- 2016-03-30 EP EP16714019.3A patent/EP3277687B1/en active Active
- 2016-03-30 DK DK16714019.3T patent/DK3277687T3/da active
- 2016-03-30 HR HRP20192195TT patent/HRP20192195T1/hr unknown
- 2016-03-30 SI SI201630560T patent/SI3277687T1/sl unknown
- 2016-03-30 ES ES16714019T patent/ES2765642T3/es active Active
- 2016-03-30 PT PT167140193T patent/PT3277687T/pt unknown
- 2016-03-30 MX MX2017011423A patent/MX2017011423A/es active IP Right Grant
- 2016-03-30 BR BR112017020131-3A patent/BR112017020131B1/pt not_active IP Right Cessation
- 2016-03-30 WO PCT/IB2016/051792 patent/WO2016157091A1/en not_active Ceased
- 2016-03-30 KR KR1020177031214A patent/KR102559190B1/ko active Active
- 2016-03-30 PL PL16714019T patent/PL3277687T3/pl unknown
- 2016-03-30 US US15/562,537 patent/US10138247B2/en active Active
- 2016-03-30 EA EA201792087A patent/EA032826B1/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017020131A2 (pt) | 2018-05-29 |
| KR102559190B1 (ko) | 2023-07-25 |
| JP2018510192A (ja) | 2018-04-12 |
| ES2765642T3 (es) | 2020-06-10 |
| HUE047822T2 (hu) | 2020-05-28 |
| EP3277687B1 (en) | 2019-10-30 |
| CN107743489B (zh) | 2021-05-04 |
| EA032826B1 (ru) | 2019-07-31 |
| DK3277687T3 (da) | 2019-12-16 |
| PL411864A1 (pl) | 2016-10-10 |
| CN107743489A (zh) | 2018-02-27 |
| EP3277687A1 (en) | 2018-02-07 |
| EA201792087A1 (ru) | 2018-03-30 |
| JP6665201B2 (ja) | 2020-03-13 |
| SI3277687T1 (sl) | 2020-02-28 |
| PL236355B1 (pl) | 2021-01-11 |
| PL3277687T3 (pl) | 2020-09-21 |
| HRP20192195T1 (hr) | 2020-03-06 |
| PT3277687T (pt) | 2020-01-10 |
| US20180111939A1 (en) | 2018-04-26 |
| BR112017020131B1 (pt) | 2023-02-28 |
| KR20170132275A (ko) | 2017-12-01 |
| CA2978828A1 (en) | 2016-10-06 |
| US10138247B2 (en) | 2018-11-27 |
| AU2016241568B2 (en) | 2019-09-26 |
| AU2016241568A1 (en) | 2017-10-19 |
| WO2016157091A1 (en) | 2016-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021553238A1 (en) | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors | |
| NZ766835A (en) | Pharmaceutical compounds | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| PH12018500437A1 (en) | Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| PH12017502171A1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| MX2016007346A (es) | Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio. | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| MX379459B (es) | Inhibidores de bromodominios. | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| EP4620528A3 (en) | Bipyrazole derivatives as jak inhibitors | |
| PH12012500752A1 (en) | Benzimidazole-imidazole derivatives | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| PH12015501836A1 (en) | 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors | |
| MX2016012669A (es) | Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y 2,3-dihidro-1h-imidazo[1,2-b]pirazol sustituidos como inhibidores de ros1. | |
| MX2015014025A (es) | Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk. | |
| MX2019010756A (es) | Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). | |
| MX2017011423A (es) | Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer. | |
| NZ761680A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| MX2019004375A (es) | Inhibidores de bromodominios. | |
| PH12020500366A1 (en) | The salts of a compound and the crystalline forms thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |